BRIEF

on Theralase Technologies Inc. (isin : CA88337V1004)

Theralase Successfully Destroys Lung Cancer

Theralase Technologies Inc. (TSXV:TLT) has announced a significant breakthrough in the preclinical treatment of Non-Small Cell Lung Cancer (NSCLC). The company's lead compound, Rutherrin®, has shown promising results in preclinical experiments using a Lewis Lung Cancer (LLC1) orthotopic model.

In the experiments, Rutherrin® exhibited a higher retention rate in lung tumors compared to normal lung tissues. This enhanced selectivity improved the compound's effectiveness in targeting lung cancer. All animals treated with x-ray activated Rutherrin® survived, in contrast to those that received only x-ray treatment.

Tumor progression was significantly slower in mice treated with Rutherrin®, with some cases showing tumor regression. Theralase plans to initiate a Phase Ia clinical study for patients with GBM and NSCLC in 4Q2024, potentially expanding to other cancers such as pancreatic, prostate, kidney, and colorectal cancer pending sufficient capital.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Theralase Technologies Inc. news